pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IONSIONIS PHARMACEUTICALS INC

$IONS43.47+0.10%
Carlsbad, CA, USupdated 20d ago

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
7
marketed
2
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(7)

pipeline depth7 products
Phase 2: 3Phase 3: 1Marketed: 2pre_registration: 1
3Phase 21Phase 32Marketed1pre_registration
Marketed
donidalorsen sodium
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketed
olezarsen sodium
Hypertriglyceridemia
Phase 3
obudanersen sodium
Angelman Syndrome
Phase 2
ION-283
Lafora Disease (Unverricht Disease)
Phase 2
ION-356
Pelizaeus-Merzbacher Disease (PMD)
Phase 2
vadernersen sodium
X Chromosome Disorders
pre_registration
zilganersen sodium
Alexander Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view IONIS PHARMACEUTICALS INC jobs →

News

  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 3d ago
  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 4d ago
  • PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
    Mean splicing correction for PepGen’s PGN-EDODM1 was 46.5% at week 13, compared to under 30% for competitors like Dyne Therapeutics, Novartis and Ionis Pharmaceuticals.
    biospace · 5d ago
  • PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag
    Plus news about Coherus Oncology, JW Therapeutics and PsiThera. PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals in a coh…
    endpoints · 6d ago
  • STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
    Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug.
    stat · 7d ago
  • Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
    Full data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…
    biospace · 7d ago
  • GSK vaccine sales miss expectations amid falling demand from adults
    With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.
    biospace · 19d ago
  • Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
    Roche's Genentech has put numbers behind its phase 3 success in IgA nephropathy (IgAN), reporting that antisense oligonucleotide sefaxersen reduced a key marker of kidney damage by 43.1% compared w…
    fiercebiotech · 25d ago
  • GSK, Ionis hepatitis B functional cure breaks open market for followers
    The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
    biospace · 25d ago
  • Why researchers may have found the biological culprit behind Angelman syndrome
    Scientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand how this gene loss leads to the failure of brain development in infants…
    fiercebiotech · 26d ago
view all news mentions →
identifiers
ticker
$IONS
SEC CIK
0000874015
country
US
source
sec_tickers
top tags
Immunology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 51m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?